Biofrontera AG, DE0006046113

Biofrontera AG, DE0006046113

05.11.2018 - 11:45:58

Biofrontera AG: Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results

Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results

Leverkusen, Germany, November 5, 2018 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the 9-month period ended September 30, 2018 on November 16, 2018.

Conference calls for shareholders and interested investors will be held on November 16, 2018 at the following times: In German, at 10:00 am CET (4:00 am ET) Dial-in number Germany: +49 (0) 69201744220 Conference code: 14005835#

In English, at 2:00 pm CET (8:00 am ET) Dial-in number USA: +1 8774230830 Dial-in number UK: +44 2030092470 Conference code: 12331554#

Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.-END-

For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer +49 (0) 214 87 63 2 0 IR UK: Seton Services Toni Vallen +44 (0) 207 224 8468 IR and PR US: The Ruth Group IR: Tram Bui PR: Kirsten Thomas +1 646-536-7035 +1 508-280-6592  

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at

Forward Looking Statements:

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.


05.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at

Language: English Company: Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen

Germany Phone: +49 (0)214 87632 0 Fax: +49 (0)214 87632 90 E-mail: Internet: ISIN: DE0006046113, NASDAQ: BFRA WKN: 604611 Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq   End of News DGAP News Service

741077  05.11.2018